# Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

> **NCT01439009** · PHASE4 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Placebo of tolvaptan

## Key facts

- **NCT ID:** NCT01439009
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439009, "Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01439009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*